Unlocking the Benefits of Inducement Grants: Adicet Bio Reports Under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET) made a major move on January 31, 2023, granting inducement awards to further its mission of discovering and developing allogeneic gamma delta T cell therapies for cancer. This clinical stage biotechnology company is paving the way for new treatments and therapies that could help those fighting cancer in the near future.

In January 2023, Adicet welcomed six new employees to the team with generous non-qualified stock option grants. Each employee was granted the opportunity to purchase 72,800 shares of Adicet’s common stock at the closing price of $9.15 per share, as reported by Nasdaq on January 31, 2023. One-fourth of the shares will vest on the one-year anniversary of each employee’s start date, and the remaining three-fourths of the shares will vest in thirty-six substantially equal monthly installments, such that the option will be fully vested on the fourth anniversary of the employee’s start date. These generous stock options are contingent on continued employment with Adicet.

In January 2022, Adicet’s board of directors adopted the 2022 Inducement Plan, which was amended in January 2023. This plan was designed to provide a material inducement to new employees entering into employment with Adicet, and awards were authorized by the compensation committee of the board of directors, comprised solely of independent directors. These awards were granted outside of Adicet’s stockholder-approved equity incentive plans, and are intended to motivate employees to perform at their best.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a pioneering biotechnology company that is revolutionizing cancer treatments with its groundbreaking gamma delta T cell therapies. Through its innovative “off-the-shelf” solutions, Adicet is engineering T cells with chimeric antigen receptors (CARs) and adaptors (CAds) to create highly-targeted treatments that trigger both innate and adaptive anti-tumor immune responses. Armed with this cutting-edge technology, Adicet is poised to revolutionize cancer treatments and improve patient outcomes.

Leave a Comment